FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

EDRICK ALAN I
2. Issuer Name and Ticker or Trading Symbol

HARVARD BIOSCIENCE INC [ HBIO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O HARVARD BIOSCIENCE, 84 OCTOBER HILL ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

9/10/2019
(Street)

HOLLILSTON, MA 01746
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy)  $2.92  9/10/2019    A     101800       (1) 9/10/2029  Common Stock, par value $0.01 per share  101800  $0.00  101800  D   

Explanation of Responses:
(1)  The options vest in three equal installments on September 10, 2020, 2021 and 2022.

Remarks:
This form has been signed under power of attorney.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
EDRICK ALAN I
C/O HARVARD BIOSCIENCE
84 OCTOBER HILL ROAD
HOLLILSTON, MA 01746
X



Signatures
/s/ Chad Porter, by power of attorney 9/11/2019
**Signature of Reporting Person Date


Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Harvard Bioscience Charts.
Harvard Bioscience (NASDAQ:HBIO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Harvard Bioscience Charts.

Harvard Bioscience Inc News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference
Friday 17 May 2024 (3 days ago) • GlobeNewswire Inc.
Form 8-K - Current report
Wednesday 15 May 2024 (5 days ago) • Edgar (US Regulatory)
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 8 May 2024 (2 weeks ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 7 May 2024 (2 weeks ago) • Edgar (US Regulatory)
Harvard Bioscience Announces First Quarter 2024 Financial Results
Tuesday 7 May 2024 (2 weeks ago) • GlobeNewswire Inc.
Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET
Monday 29 April 2024 (3 weeks ago) • GlobeNewswire Inc.
Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth
Tuesday 9 April 2024 (1 month ago) • GlobeNewswire Inc.
Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti’s Small Cap Conference and KeyBanc’s Life Sciences & MedTech Conference
Monday 11 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)